Vancomycin-Resistant Staphylococcus aureus (VRSA) Drugs Market Size, Share and Global Trend By Product (Linezolid, Tigecycline, Daptomycin, Telavancin, Ceftaroline, Quinupristin, Dalfopristin, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2024-2032

The human body is a host of a variety of microbial flora. One among them is Staphylococcus aureus, a gram-positive bacterium, which is most commonly found on the skin as well as nasal passages of humans. According to the Department of Health, 20% of the human population is always colonized with Staphylococcus aureus. Being a facultative anaerobe, it can cause respiratory diseases, skin illness, and food poisoning. Apart from a Staph infection, it is also the common causative agent for illness such as boils, impetigo, pimples, abscesses and certain serious diseases such as pneumonia, meningitis, osteomyelitis, sepsis, and others.

According to the Health Research Funding Organization, there are 19,000 deaths worldwide due to Staph infection every year. According to Centre of Disease Control and Prevention, there were 13 cases in 4 states of U.S., during 2002-2013. In due course of time, the species of Staphylococcus aureus have developed resistance to many of the antimicrobial drugs. For example, MRSA, a class of Staphylococcus aureus which are resistant to Methicillin.

Similarly, vancomycin-resistant Staphylococcus aureus is one of the strains of Staphylococcus aureus resistant to the antibiotic vancomycin or glycopeptides. There are three types of vancomycin-resistant Staphylococcus aureus namely high-level VRSA, vancomycin-intermediate S. aureus (VISA) and heterogeneous VISA (hVISA). According to the Texas Department of State Health Services, there were 13 cases of VISA in 2016 in Texas.

The growth in global vancomycin-resistant Staphylococcus aureus drugs market is being driven by an increased incidence of diseases caused by VRSA, poor sanitation which in turn increases the risk of hospital-acquired infection. In addition to that, increased awareness program and government funding in research and developments of new drugs are expected to drive the market growth.

Certain factors such as the increased usage of generic alternatives especially due to the loss of patents, the short lifecycle of the drugs and the anticipated slower growth due to the increasing maturity of the market are expected to limit the growth of the global vancomycin-resistant Staphylococcus aureus (VRSA) drugs market.

Key Players Covered

Some of the major companies that are present in the global Vancomycin-Resistant Staphylococcus aureus (VRSA) Drugs market are GlaxoSmithKline, AstraZeneca Plc, Cubist Pharmaceutical, Forest Laboratories, Debiopharm International, iNtRON Biotechnology, Crystal Genomics, Wockhardt Limited, Destiny Pharma Ltd, Therapeutic Systems Research Laboratories Inc., and others.

SEGMENTATION

Among the segmentation, Linezolid in the drug class segment is projected to hold a considerable share of the global Vancomycin-Resistant Staphylococcus aureus (VRSA) drugs market due to higher adoption of linezolid and the ability of the linezolid to able to fight against a number of gram-positive bacterial infections.

 Key Insights

• Epidemiological Analysis and Prevalence of Diseases Caused by VRSA for Key Countries
• Pipeline Analysis
• Recent Industry Developments such as Partnerships, Mergers, and Acquisitions
• Patent Analysis
• New Product Launches

Regional Analysis

North America is anticipated to hold a considerable share of the global vancomycin-resistant Staphylococcus aureus (VRSA) drugs market owing to increasing incidences of VRSA infections, increasing R&D initiatives and the increasing demand for novel therapeutics. The Asia Pacific holds potential for Vancomycin-Resistant Staphylococcus aureus (VRSA) Drugs owing to the rise in prevalence of chronic diseases and increasing development of healthcare infrastructure. One of the other key contributors to the growth in this region is the increasing number of pharmaceutical manufacturers and also the high adoption of generic medications.

Key Industry Developments

• In February 2019, scientists at Rutgers University discovered two genes that enable infections such as VRSA resistant to treatment
• In November 2018, Roivant Sciences and iNtRON Bio entered into a licensing deal for a novel anti- superbugs biologic called SAL200, that will enable the treatment of VRSA infections. SAL200 in its pre-clinical studies showed bacterial activity against the pathogen of VRSA.